Japanese encephalitis virus, inactivated
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2009
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Japanese encephalitis virus, inactivated
- ixiaro
- Ixiaro
- ixiaro
- Ixiaro
- IXIARO
- IXIARO®
- japanese encephalitis virus inactivated
- Japanese encephalitis virus, inactivated
- ChEMBL ID
- CHEMBL6068364
- RxNorm IDs (RxCUI)
- 1300779
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Encephalitis, Japanese
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007332
- Subject identifier
- D004672
Open Targets indications
- Condition identifier
- EFO_0007332
- Highest recorded phase
- 3
- Event
- urticaria
- Reports
- 3
- Reporting signal score
- 8.97285
- Event
- urticaria chronic
- Reports
- 3
- Reporting signal score
- 24.754
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (9)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
- Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine
- Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.
- Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
- This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population